|Bid||43.5000 x 1000|
|Ask||43.4900 x 1100|
|Day's Range||42.7800 - 43.5000|
|52 Week Range||33.2000 - 45.8100|
|Beta (3Y Monthly)||0.73|
|PE Ratio (TTM)||10.91|
|Earnings Date||Jan 28, 2019 - Feb 1, 2019|
|Forward Dividend & Yield||1.36 (3.13%)|
|1y Target Est||43.79|
On November 20, Pfizer (PFE) closed at $43.53, which was 1.47% lower than its previous closing price. On November 19, Pfizer and Merck KGaA issued a press release announcing unfavorable results from the Phase 3 trial, JAVELIN Ovarian 200, evaluating avelumab in ovarian cancer indication.
As the market grows increasingly turbulent and economic outlooks become more cautious, investors are increasingly buying quality stocks, which by definition are stocks whose companies are not overly reliant on a robust economy for their performance. In the current environment, Walmart Inc. ( WMT), McDonald’s Corp. ( MCD), Pfizer Inc. ( PFE), Procter & Gamble Co. ( PG) and Amgen Inc. ( AMGN) have all received the quality stamp of approval by Citigroup, according to CNBC.
The savage sell-off of US technology stocks broadened into a global market retreat on Tuesday, stoked by investor fears around trade tension, slowing economic growth and weak corporate earnings in the US, Asia and Europe. The Nasdaq Composite index ended a turbulent trading day down 1.7 per cent, nearly wiping out the last of its gains for the year. It fell 1.8 per cent.
The Nasdaq got smacked with its biggest single-session loss in more than three weeks and nearly faced a test of the psychologically important 7000 level.
Diversis Capital Buys Controlling Stake of Tempo Diversis Capital acquired a controlling interest in Tempo, an Icelandic provider of time-tracking, resource-management and budgeting software. Information-technology services company Origo hf.
Pfizer’s (PFE) stock price opened at $36.23 on January 2 and reached $43.51 on November 16, which represents ~20.0% growth year-to-date. Pfizer’s stock price closed at $43.51 on November 16, which represents ~31% growth from its 52-week low of $33.20 on February 9.
My weekend scanning revealed one prominent theme: The healthcare sector is one of the strongest on the Street making many of its constituents the best stocks to buy for the week ahead. Volume patterns are supporting an optimistic view with numerous accumulation days forming after last month’s earnings report.
The selling began early and intensified throughout the day as investors sold nearly everything in sight. Of course, there were a few stocks and sectors that avoided the damage, like Coca-Cola , Verizon and Pfizer , but they were lonely greenshoots in a sea of red. Tech stocks led the bleeding as they have since August, and the headlines were ugly.
pushed higher on Monday despite defying White House demands to control prices and a broader market selloff. Caitlin Oakley, a spokeswoman for the U.S. Department of Health and Human Services, lambasted the company's move in a statement to Real Money. "Actions announced Friday on list prices further illustrate the perverse incentives of America's drug pricing system," she wrote.
Pfizer will raise prices on 41 drugs starting January 15, 2019, despite pressure from Trump. Yahoo Finance’s Alexis Christoforous and Communications Director Campaign for Sustainable Rx Pricing Lauren Blair discuss.